Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13212373 | 0.91 | CETP (0.73) | CETP | |
| SCHEMBL1524867 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL1524730 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL1524618 | 0.90 | CETP (0.77) | CETP | |
| SCHEMBL1525526 | 0.90 | CETP (0.77) | CETP | |
| SCHEMBL528430 | 0.90 | CETP (0.77) | CETP | |
| SCHEMBL993460 | 0.90 | CETP (0.76) | CETP | |
| SCHEMBL1900745 | 0.89 | CETP (0.76) | CETP | |
| SCHEMBL13212570 | 0.89 | CETP (0.76) | CETP | |
| SCHEMBL13212497 | 0.89 | CETP (0.76) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-2292596-A2 | CETP activity inhibitor | Japan Tobacco, Inc. (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7271196-B2 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TABACCO INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-7271196-B2 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TABACCO INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-7271196-B2 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TABACCO INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | CETP 64/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885 |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | CETP, PCSK9, LCAT | CETP 1/4885 |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.